These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32983101)

  • 41. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    Bressler B; Yarur A; Silverberg MS; Bassel M; Bellaguarda E; Fourment C; Gatopoulou A; Karatzas P; Kopylov U; Michalopoulos G; Michopoulos S; Navaneethan U; Rubin DT; Siffledeen J; Singh A; Soufleris K; Stein D; Demuth D; Mantzaris GJ
    J Crohns Colitis; 2021 Oct; 15(10):1694-1706. PubMed ID: 33786600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud D; Vermeire S; Verstockt B
    Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
    Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
    J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imbalance of Circulating Innate Lymphoid Cell Subpopulations in Patients With Septic Shock.
    Carvelli J; Piperoglou C; Bourenne J; Farnarier C; Banzet N; Demerlé C; Gainnier M; Vély F
    Front Immunol; 2019; 10():2179. PubMed ID: 31616411
    [No Abstract]   [Full Text] [Related]  

  • 46. Innate Lymphoid Cells Have Decreased HLA-DR Expression but Retain Their Responsiveness to TLR Ligands during Sepsis.
    Cruz-Zárate D; Cabrera-Rivera GL; Ruiz-Sánchez BP; Serafín-López J; Chacón-Salinas R; López-Macías C; Isibasi A; Gallegos-Pérez H; León-Gutiérrez MA; Ferat-Osorio E; Arriaga-Pizano L; Estrada-García I; Wong-Baeza I
    J Immunol; 2018 Dec; 201(11):3401-3410. PubMed ID: 30373848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained Post-Developmental T-Bet Expression Is Critical for the Maintenance of Type One Innate Lymphoid Cells
    Schroeder JH; Roberts LB; Meissl K; Lo JW; Hromadová D; Hayes K; Zabinski T; Read E; Moreira Heliodoro C; Reis R; Howard JK; Grencis RK; Neves JF; Strobl B; Lord GM
    Front Immunol; 2021; 12():760198. PubMed ID: 34795671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute Experimental Barrier Injury Triggers Ulcerative Colitis-Specific Innate Hyperresponsiveness and Ulcerative Colitis-Type Microbiome Changes in Humans.
    Seidelin JB; Bahl MI; Licht TR; Mead BE; Karp JM; Johansen JV; Riis LB; Galera MR; Woetmann A; Bjerrum JT
    Cell Mol Gastroenterol Hepatol; 2021; 12(4):1281-1296. PubMed ID: 34118489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotypic shift of small intestinal intra-epithelial type 1 innate lymphoid cells in celiac disease is associated with enhanced cytotoxic potential.
    Uhde M; Yu X; Bunin A; Brauner C; Lewis SK; Lebwohl B; Krishnareddy S; Alaedini A; Reizis B; Ghosh S; Green PH; Bhagat G
    Clin Exp Immunol; 2020 May; 200(2):163-175. PubMed ID: 31907928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigating the impact of antibiotic-induced dysbiosis on protection from
    Uddin MJ; Thompson B; Leslie JL; Fishman C; Sol-Church K; Kumar P; Petri WA
    mBio; 2024 Mar; 15(3):e0333823. PubMed ID: 38376154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3.
    Koh J; Kim HY; Lee Y; Park IK; Kang CH; Kim YT; Kim JE; Choi M; Lee WW; Jeon YK; Chung DH
    Clin Cancer Res; 2019 Jul; 25(13):4026-4037. PubMed ID: 30979738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TNF-α Producing Innate Lymphoid Cells (ILCs) Are Increased in Active Celiac Disease and Contribute to Promote Intestinal Atrophy in Mice.
    Marafini I; Monteleone I; Di Fusco D; Cupi ML; Paoluzi OA; Colantoni A; Ortenzi A; Izzo R; Vita S; De Luca E; Sica G; Pallone F; Monteleone G
    PLoS One; 2015; 10(5):e0126291. PubMed ID: 25950701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The differential frequency of Lineage(-)CRTH2(-)CD45(+)NKp44(-)CD117(-)CD127(+)ILC subset in the inflamed terminal ileum of patients with Crohn's disease.
    Li J; Doty AL; Iqbal A; Glover SC
    Cell Immunol; 2016; 304-305():63-8. PubMed ID: 27215784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
    Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
    Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues.
    Bernink JH; Peters CP; Munneke M; te Velde AA; Meijer SL; Weijer K; Hreggvidsdottir HS; Heinsbroek SE; Legrand N; Buskens CJ; Bemelman WA; Mjösberg JM; Spits H
    Nat Immunol; 2013 Mar; 14(3):221-9. PubMed ID: 23334791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.
    Yadav A; Foromera J; Feuerstein I; Falchuk KR; Feuerstein JD
    Inflamm Bowel Dis; 2017 Jun; 23(6):853-857. PubMed ID: 28509816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cross-talk between RORγt+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease.
    Mizuno S; Mikami Y; Kamada N; Handa T; Hayashi A; Sato T; Matsuoka K; Matano M; Ohta Y; Sugita A; Koganei K; Sahara R; Takazoe M; Hisamatsu T; Kanai T
    Inflamm Bowel Dis; 2014 Aug; 20(8):1426-34. PubMed ID: 24991784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.